...A. I joined Pfizer through the acquisition of Seagen, where I spent more than 12 years, and most recently led both early and late stage clinical development. B. And finally, with the acquisition of Seagen, we have an industry-leading platform and know-how to deliver ADCs or antibody drug conjugates, a modality that very neatly sits at the intersection of small molecules and biologics. C. Specifically, we continue to build on Pfizer's established presence in breast cancer, as we will focus on today, along with Genitourinary cancers, Hematologic Malignancies, and Thoracic cancers. D. For example, the practice changing results with the combination of BRAFTOVI, cetuximab, and modified FOLFOX6, as reported recently at ASCO for our breakwater trial in BRAF-mutant colorectal cancer. E. The majority, approximately 65% to 70% of breast cancers are HR+, HER2 negative. F. HER2 positive cancers occur in about 15% to 20% of patients, and treatment includes HER2 targeted ADCs and Tyrosine kinase inhibitors....
